---
truth_dimension: orientation
authority_level: advisory
mutation_path: readme_update
---

# Controlled Early Human-Use Trial Boundary - Phase 122

## Scope
Phase 122 is controlled early-human-use trial boundary only. It defines the procedure, participant constraints, role ownership, manual-review posture, evidence capture, stop-condition handling, escalation handling, and Phase 123 handoff requirements for a bounded non-public/local trial under the Phase 120 constrained early-human-use candidate posture.

Phase 122 does not approve Release Candidate status, release-candidate readiness, Production Candidate status, production readiness, public usability, public/general use, production deployment, or production human use.

## Evidence rule
Only committed repository evidence counts: source files, tests, UI behavior tests, validation scripts, governance docs, architecture docs, roadmap docs, operations docs, changelog surfaces, checklists, schemas, and CI/workflow files.

Prompt intent, prior chat summaries, uncommitted work, speculative roadmap claims, future phase descriptions as implemented behavior, validation success as release approval, validation success as readiness approval, Phase 120 constrained early-human-use candidacy as public/general use, Phase 121 roadmap expansion as trial completion, Phase 117 dry-run documentation as controlled trial completion, Phase 116 local deployment candidacy as release readiness, Phase 115 security audit evidence as public-use approval, and absence of blockers as approval do not count.

## Phase 122 trial boundary
Phase 122 may define and record controlled early-human-use trial procedure, participant constraints, evidence capture, stop-condition handling, manual-review disposition, and escalation disposition. Phase 122 may not broaden trial authority beyond Phase 120 constraints.

The trial boundary is local/non-public, named-participant, manually reviewed, Trial-coordinator-owned, and evidence-capture-required. The status for the boundary is `trial_boundary_defined` until actual trial records are captured and reviewed in a future permitted surface.

## Controlled early-human-use trial is not public/general use
Controlled early-human-use trial evidence is trial evidence only. It is not public/general-use approval, public usability, general availability, public distribution, public download approval, or public release behavior.

## Controlled early-human-use trial is not Release Candidate approval
Controlled early-human-use trial evidence is not Release Candidate approval, release-candidate readiness, release approval, release artifact creation, or release readiness.

## Controlled early-human-use trial is not Production Candidate approval
Controlled early-human-use trial evidence is not Production Candidate approval and cannot satisfy Production Candidate requirements by inheritance.

## Controlled early-human-use trial is not production human use
Controlled early-human-use trial evidence is not production human-use approval, production readiness, production deployment, or production status.

## Trial status model
Permitted Phase 122 trial statuses are:

- `trial_boundary_defined`
- `trial_evidence_recorded`
- `trial_blocked`
- `trial_deferred`
- `trial_requires_manual_review`
- `trial_stop_condition_active`
- `trial_ready_for_phase_123_review`
- `not_applicable`

Prohibited statuses include `approved`, `production_ready`, `release_ready`, `public_ready`, `controlled_human_use_approved`, `production_human_use_approved`, `release_candidate_approved`, and `production_candidate_approved`.

## Phase 120 relationship
Phase 120 is complete and remains Early Human-Use Candidate Gate only. Phase 120 permitted `early_human_use_candidate_permitted_with_constraints` under a bounded, non-public, local/trial-only, manually reviewed posture constrained to named internal/trial participants.

Phase 122 preserves those constraints and does not reinterpret Phase 120 as Release Candidate approval, Production Candidate approval, public/general use, production readiness, production deployment, or production human use.

## Phase 121 relationship
Phase 121 is complete and remains roadmap expansion and production gap reassessment only. Phase 121 mapped Phase 122 as controlled early-human-use trial work only, Phase 125 as the next 0/5 checkpoint, and Phase 130 as Release Candidate Decision Gate only.

Phase 122 does not treat Phase 121 roadmap expansion as trial completion, release approval, Production Candidate approval, public/general-use approval, production readiness, production deployment, or production human-use approval.

## Ladder-Preservation Invariant Set
1. Ladder steps are not interchangeable; each rung is a distinct authority boundary.
2. No implicit promotion: trial success, validation success, operator notes, human feedback, or absence of blockers cannot promote Release Candidate status, Production Candidate status, public/general use, production readiness, or production human use.
3. Absence of blockers is not approval.
4. Evidence assembly is not readiness.
5. Dry runs are not release and create no release artifacts, installers, update channels, signing metadata, public downloads, or release readiness.
6. Decision gates may approve only their explicitly authorized decision; Phase 122 is not a release, Production Candidate, public/general-use, or production-use decision gate.
7. No phase may retroactively rewrite earlier gates; Phase 122 evidence cannot reinterpret Phase 120 as release, Production Candidate, or public-use approval.
8. Human use is not binary; controlled early-human-use trial evidence is distinct from Release Candidate, Production Candidate, and public/general-use evidence.
9. Deployment is not release; deployment configuration and local deployment candidate evidence do not imply release, public usability, readiness, production deployment, or production status.
10. No phase may claim to be the final gate; Phase 122 is not the end of the roadmap.
11. Public/general use is always the final rung.
12. No trust inference: provider output, operator notes, participant notes, or feedback do not imply trust, readiness, safety, or authority.
13. No cross-category inference: trial evidence, usability evidence, operator workflow evidence, observability evidence, security evidence, release evidence, and governance evidence remain separate.
14. No phase may activate authority without explicit roadmap permission; persistence, replay, recovery, action execution, provider trust, readiness, release, deployment, and public-use authority remain off unless explicitly activated by a future phase.
15. Every rung requires its own evidence, not inherited evidence; Phase 122 evidence may support Phase 123 review but cannot satisfy Release Candidate, Production Candidate, or public/general-use evidence requirements by inheritance.
16. Roadmap continuation remains required; later rungs remain mapped to later phases and must not be inferred from Phase 122 trial work.

## Production-human-use ladder
The staged ladder remains:

1. Local operator testing
2. Controlled human trial
3. Early human-use candidate
4. Release candidate
5. Production candidate
6. Public/general use

Phase 122 operates only within the Early human-use candidate rung. It does not collapse, merge, reorder, skip, or approve later rungs. Public/general use remains a later final rung.

## Trial participant boundary
Participants are limited to named internal/trial participants explicitly accepted by the Trial coordinator for the local/non-public trial. Anonymous users, public users, production users, broad internal distribution, and general availability audiences are outside the boundary.

## Named participant requirements
Each participant record must identify the named internal/trial participant, the trial session, the local/non-public context, the manual-review owner, the evidence capture location, and any restrictions acknowledged before participation.

## Trial coordinator ownership
A named Trial coordinator owns the trial boundary, participant list, session scheduling, evidence completeness, stop-condition evaluation, manual-review disposition routing, and Phase 123 handoff package. Without a named Trial coordinator, status is `trial_blocked` or `trial_deferred`.

## Operator responsibilities
Operators must keep the trial local/non-public, use only permitted existing validation/reporting surfaces, avoid production claims, collect session evidence, mark uncertainty, preserve raw feedback as untrusted evidence, stop on stop conditions, and route exceptions to the Trial coordinator.

## Reviewer responsibilities
Reviewers must perform manual review before any trial evidence is treated as usable for Phase 123 review, keep evidence categories separate, reject readiness language, verify stop-condition handling, and ensure prohibited authority categories remain off.

## Security reviewer escalation
Security issues, suspected abuse paths, provider-output trust concerns, sensitive-data exposure, network exposure, permission drift, filesystem mutation outside existing permitted surfaces, or action-execution concerns require Security reviewer escalation. Escalation status may be `trial_requires_manual_review`, `trial_stop_condition_active`, `trial_blocked`, or `trial_deferred`; it is never readiness approval.

## Release steward escalation
Release, public-use, deployment, packaging, installer, update-channel, signing, publishing, GitHub release, release tag, public download, release-readiness, Release Candidate, Production Candidate, public-usability, production-readiness, production-deployment, or production-human-use claims require Release steward escalation. Escalation records are non-approval records.

## Manual-review posture
Manual review is required for participant admission, session evidence, feedback evidence, stop-condition disposition, Security reviewer escalation, Release steward escalation, residual-risk carry-forward, and Phase 123 handoff. Automated validation output is evidence only and cannot approve readiness.

## Local/non-public trial posture
The trial remains bounded, non-public, local/trial-only, and constrained to named internal/trial participants. Phase 122 adds no background services, daemon behavior, active deployment automation, production deployment behavior, public release behavior, or network expansion.

## Evidence capture requirements
Evidence capture must record trial status, participant boundary, named participants, Trial coordinator, operators, reviewers, Security reviewer escalations, Release steward escalations, manual-review disposition, local/non-public posture, session evidence, feedback evidence, stop conditions, success/failure criteria, residual risks, and Phase 123 handoff status.

## Trial session evidence expectations
Each trial session evidence record should include session identifier, date, named participant, Trial coordinator, operator, reviewer, local environment summary, surfaces used, validation commands run, observed outcomes, stop-condition checks, manual-review disposition, and residual-risk notes.

## Trial feedback evidence expectations
Feedback evidence should preserve participant notes, operator notes, reviewer notes, friction points, confusing UI or workflow states, suspected safety issues, suspected release/public-use language, and suggested follow-ups as untrusted descriptive evidence. Feedback does not imply trust, readiness, safety, authority, public usability, or approval.

## Stop conditions
Stop conditions include security issue discovery, public-use claim, release-readiness claim, Production Candidate claim, production-readiness claim, production-deployment claim, production-human-use claim, provider-output trust claim, action-execution attempt, replay-repair attempt, recovery-promotion attempt, persistence-authority expansion attempt, deployment automation attempt, release artifact/package/installer/update/signing/publishing/GitHub release/tag/public asset attempt, participant-boundary breach, missing Trial coordinator, missing manual review, missing evidence capture, or unresolved sensitive-data concern.

## Success criteria
Phase 122 succeeds only when the controlled trial boundary is documented, Phase 120 constraints are preserved, Phase 121 planning relationships are preserved, participant boundaries are explicit, named role ownership is explicit, manual review and escalations are explicit, evidence capture and stop conditions are explicit, Phase 123 handoff expectations are explicit, and no later-rung approval or behavior is introduced.

## Failure criteria
Phase 122 fails or is blocked if it expands authority beyond Phase 120 constraints, introduces release/deployment/provider/persistence/replay/recovery/action behavior, treats absence of blockers as approval, uses prohibited status terms, omits Trial coordinator ownership, omits named participant requirements, omits manual review, omits Security reviewer or Release steward escalation, collapses evidence categories, or implements Phase 123.

## Residual-risk carry-forward
Residual risks remain descriptive and must be carried forward to Phase 123 review without promotion. Unresolved participant, security, release-boundary, usability, operator-workflow, observability, governance, provider-output, persistence, recovery, replay, action-execution, deployment, or public-use risks remain open until a future authorized phase addresses them.

## Evidence-category separation
Trial evidence, usability evidence, operator workflow evidence, observability evidence, security evidence, release evidence, governance evidence, roadmap evidence, changelog evidence, and validation evidence remain separate. No cross-category inference is permitted.

## Provider-output and human-feedback trust prohibition
Provider output and human feedback are untrusted descriptive inputs. Phase 122 does not add provider trust, does not promote provider output, and does not infer readiness, safety, authority, or approval from participant notes, operator notes, reviewer notes, or absence of negative feedback.

## Phase 123 evidence handoff
The Phase 123 handoff package should include boundary definition, participant list, Trial coordinator record, operator/reviewer records, manual-review dispositions, session evidence, feedback evidence, stop-condition log, escalations, residual-risk list, and explicit non-approval statements.

## Phase 123 review expectation
Phase 123, if recommended, is early human-use evidence review and operator feedback audit only. Phase 123 is not implemented by Phase 122 and is not release readiness, Production Candidate readiness, public/general-use approval, production deployment, or production human-use approval.

## Release artifact prohibition
Phase 122 does not create release artifacts, packages, release bundles, public downloads, or public assets.

## Deployment automation prohibition
Phase 122 does not add deployment automation, production deployment behavior, background services, daemon behavior, deployment scripts, or active production infrastructure.

## Installer/update-channel prohibition
Phase 122 does not create installer behavior or update-channel behavior.

## Signing/publishing prohibition
Phase 122 does not add signing behavior, publishing behavior, signature metadata, distribution metadata, or public distribution behavior.

## GitHub release/tag/public asset prohibition
Phase 122 does not create GitHub releases, release tags, public downloads, public assets, or public release assets.

## Public-release prohibition
Phase 122 does not add public release behavior and does not authorize public release claims.

## Production-deployment prohibition
Phase 122 does not add production deployment behavior and does not authorize production deployment claims.

## Public/general-use approval prohibition
Phase 122 does not approve public/general use, public usability, public distribution, or general availability.

## Production-human-use approval prohibition
Phase 122 does not approve production human use.

## Production Candidate approval prohibition
Phase 122 does not approve Production Candidate status.

## Release-candidate approval prohibition
Phase 122 does not approve Release Candidate status or release-candidate readiness.

## Provider trust/output promotion prohibition
Phase 122 does not add provider trust, trust provider output, or promote provider output.

## Replay-repair prohibition
Phase 122 does not add replay repair.

## Recovery-promotion prohibition
Phase 122 does not add recovery promotion.

## Action-execution prohibition
Phase 122 does not add action execution.

## Readiness approval prohibition
Phase 122 does not approve readiness, production readiness, release readiness, public readiness, or human-use readiness.

## Required future implementation evidence
Any future trial execution evidence, Phase 123 review, remediation, Release Candidate decision, Production Candidate decision, public/general-use decision, deployment behavior, release artifact behavior, provider trust, persistence expansion, replay repair, recovery promotion, or action execution requires separate committed evidence and explicit future-phase authority.

## Phase 123 gate decision
Phase 123 is not implemented. If reached, Phase 123 may review early human-use evidence and operator feedback only; it may not approve readiness or later rungs.

## Phase 125 checkpoint expectation
Phase 125 remains the next 0/5 checkpoint and must reconcile Phase 121-124 outcomes before release-candidate hardening may proceed.

## Phase 130-or-later deferrals
Phase 130 remains Release Candidate Decision Gate only. Production Candidate status, production readiness, production deployment, production human use, and public/general use remain deferred to Phase 130 or later gates as explicitly mapped by roadmap planned truth.

## Production Candidate status
Production Candidate status is not approved.

## Release-candidate readiness status
Release-candidate readiness is not approved.

## Public/general use status
Public/general use is not approved and remains a later final rung.

## Roadmap/changelog truth posture
Roadmap remains planned truth. CHANGELOG surfaces remain historical truth. This Phase 122 report is advisory orientation evidence for the controlled early-human-use trial boundary and does not supersede governance, architecture, roadmap, changelog, or checklist authority.

## Required follow-ups
Carry the Phase 122 handoff package into Phase 123 review if a future phase opens that work. Preserve Phase 120 constraints, Phase 121 roadmap expansion, Phase 125 checkpoint expectations, Phase 130 Release Candidate Decision Gate separation, and later-rung deferrals.

## Deferred items
Release artifacts, packages, installers, update channels, signing, publishing, GitHub releases, release tags, public downloads, public assets, public release, production deployment, deployment automation, background services, daemon behavior, provider execution expansion, persistence authority expansion, replay repair, recovery promotion, action execution, provider trust, provider output promotion, readiness approval, Release Candidate approval, Production Candidate approval, public/general-use approval, and production-human-use approval remain deferred.

## Confirmed vs suspected
Confirmed: Phase 122 defines the controlled early-human-use trial boundary, required roles, named participant constraints, manual review, escalation paths, evidence capture, stop conditions, success/failure criteria, and Phase 123 handoff expectations. Suspected or speculative trial outcomes, readiness claims, release claims, production claims, public-use claims, provider-trust claims, and future phase implementations were not counted.

## Non-readiness statement
Phase 122 is controlled early-human-use trial boundary only. It is not Release Candidate approval, not release-candidate readiness, not Production Candidate approval, not production readiness, not production deployment, not public usability, not public/general use, and not production human use.
